Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients:a systematic review and meta-analysis
- Author:
Saeed KHORRAMNIA
1
;
Zia NAVIDI
;
Amirhossein ORANDI
;
Mojgan Mohajeri IRAVANI
;
Amirali ORANDI
;
Ebadallah Shiri MALEKABAD
;
Seyed Hamid Pakzad MOGHADAM
Author Information
- Publication Type:Original Article
- From: Clinical Transplantation and Research 2024;38(2):136-144
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Tixagevimab/cilgavimab (Tix/Cil) shows promise as a prophylactic treatment against coronavirus disease 2019 (COVID-19) in solid organ transplant recipients (SOTRs). This study was performed to assess the effectiveness of Tix/Cil for preexposure prophylaxis against COVID-19 in this population.
Methods:We systematically searched the Cochrane Library, Web of Science, PubMed, and Embase databases to identify articles relevant to our study up to December 15, 2023. Comprehensive Meta-Analysis (ver. 3.0) was used for data analysis.
Results:The meta-analysis included seven eligible retrospective studies, encompassing a total of 4,026 SOTRs. The analysis revealed significant differences in SOTRs who received Tix/Cil preexposure prophylaxis relative to those who did not. Specifically, these differences were observed in the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (odds ratio [OR], 0.30; 95% confidence interval [CI], 0.15–0.60), hospitalization (OR, 0.24; 95% CI, 0.08–0.70), and intensive care unit admission (OR, 0.07; 95% CI, 0.02–0.22). However, mortality rate did not differ significantly between the two groups (P=0.06).
Conclusions:The evidence supporting the effectiveness of Tix/Cil as preexposure prophylaxis against SARS-CoV-2 in SOTRs is of a low to moderate level. Further high-quality research is necessary to understand its effects on this population.
